Frontiers in drug deliveryPub Date : 2026-08-28eCollection Date: 2026-01-01DOI: 10.3389/fddev.2026.1894135
Sarah Maryon Hayes, Daniel F Pease, Christine M Wiese, Marshall Mazepa
{"title":"Case report: Caplacizumab without plasma exchange for severe thrombotic thrombocytopenic purpura.","authors":"Sarah Maryon Hayes, Daniel F Pease, Christine M Wiese, Marshall Mazepa","doi":"10.3389/fddev.2026.1894135","DOIUrl":"10.3389/fddev.2026.1894135","url":null,"abstract":"<p><p>A 45-year-old female Jehovah's Witness presented with transient expressive aphasia, blurred vision, and dizziness for several hours. A complete blood count (CBC) showed anemia (hemoglobin: 6.3 g/dL), thrombocytopenia (platelet count: 21 × 10<sup>3</sup>/µL), and undetectable haptoglobin. The peripheral smear revealed schistocytes, confirming microangiopathic hemolytic anemia; immune-mediated thrombotic thrombocytopenic purpura (iTTP) was confirmed with an ADAMTS13 level of less than 5% and a positive ADAMTS13 inhibitor screen. Treatment with high-dose corticosteroids was urgently initiated, but the patient and her husband declined plasma exchange based on their beliefs as Jehovah's Witnesses. The patient acutely decompensated, requiring intubation, with worsening of laboratory values (hemoglobin: 3.8 g/dL; platelet count: 9 × 10<sup>3</sup>/µL), elevated serum troponin, and renal and hepatic compromise. In addition to rituximab and intravenous immune globulin, caplacizumab therapy was undertaken. The patient's condition improved clinically, but from a laboratory value perspective, 1 month after caplacizumab initiation, her ADAMTS13 level remained less than 5%. Further immunosuppression with intravenous cyclophosphamide was initiated, which resulted in complete normalization of ADAMTS13 activity. This is the first report of caplacizumab use in a Jehovah's Witness patient with TTP with severe neurological compromise to the point of necessitating intubation and with this degree of anemia. With the eventual addition of cyclophosphamide therapy, we observed complete recovery of this critically ill patient without the use of plasma exchange in the treatment course.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"6 ","pages":"1894135"},"PeriodicalIF":4.4,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13562035/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148957470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in drug deliveryPub Date : 2026-08-21eCollection Date: 2026-01-01DOI: 10.3389/fddev.2026.1839747
Lisa Myrseth Hemmingsen, Marte Kristensen, Cecilie Thanh Loan Dang, Mari Salamonsen, Elizabeth G Aarag Fredheim, Nataša Škalko-Basnet
{"title":"Harnessing liposomal delivery to boost polyphenols' potential in chronic wound therapy.","authors":"Lisa Myrseth Hemmingsen, Marte Kristensen, Cecilie Thanh Loan Dang, Mari Salamonsen, Elizabeth G Aarag Fredheim, Nataša Škalko-Basnet","doi":"10.3389/fddev.2026.1839747","DOIUrl":"10.3389/fddev.2026.1839747","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic wounds pose a significant clinical challenge due to impaired healing, persistent inflammation, and susceptibility to infection, often by antimicrobial-resistant bacteria. Therefore, active compounds should ideally act both as antimicrobials with limited potential for resistance development and offer other beneficial wound-healing properties. Polyphenols, such as chlorogenic acid (CGA) and quercetin (QCT), exhibit those properties, but are limited by poor stability or low bioavailability.</p><p><strong>Methods: </strong>In this study, liposomal formulations of CGA (CGA-LP) and QCT (QCT-LP) were tailored to overcome delivery barriers to wound sites. Liposomes were characterized by size, size distribution, zeta potential, entrapment efficiency, and stability.</p><p><strong>Results and discussion: </strong><i>In vitro</i> release studies for CGA-LP and QCT-LP demonstrated sustained payload release of ∼30% and ∼50%, respectively, over 24 h. Antioxidant activity of both compounds was assessed using DPPH and ABTS·<sup>+</sup> assays, confirming the radical scavenging potential of CGA comparable to vitamins C and E, while QCT showed high DPPH activity, but limited ABTS·<sup>+</sup> activity. Biocompatibility studies on murine macrophages revealed no cytotoxicity for either formulation. Antibacterial activity was assessed via broth microdilution for both formulations and isothermal microcalorimetry for CGA-LPs. Only QCT-LP potent measurable inhibitory effects against <i>Staphylococcus aureus</i> in the broth microdilution assay; however, effects on metabolic activity were observed for CGA-LPs. These findings suggest that liposomal entrapment could protect polyphenols and prolong or tailor their release, potentially offering a promising strategy for chronic wound therapy and addressing challenges associated with oxidative stress and bacterial infections.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"6 ","pages":"1839747"},"PeriodicalIF":4.4,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13541760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148898135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Engineering a medical device for intranasal immunisation: ensuring targeted delivery and formulation stability.","authors":"Gonçalo Farias, Arnaud Bude, Nektaria Karavas, Christelle Rossignol, Isabelle Lantier, Julie Suman, Nicolas Aubrey, Isabelle Dimier-Poisson, Mathieu Epardaud","doi":"10.3389/fddev.2026.1875011","DOIUrl":"10.3389/fddev.2026.1875011","url":null,"abstract":"<p><strong>Introduction: </strong>The efficacy of nasal vaccination critically depends on the delivery method, which must ensure precise and reproducible deposition of the vaccine within the nasal cavity to effectively stimulate mucosal immune structures such as the nasalx{2011}associated lymphoid tissue (NALT). Transitioning from prex{2011}clinical models to human applications is challenging because of anatomical and physiological differences in nasal structure and airflow dynamics.</p><p><strong>Methods: </strong>We developed a nasalx{2011}spray device specifically designed for human nasal immunization. The device delivers a broad, homogeneous spray that is confined to the nasal cavity, thereby avoiding the lower respiratory tract and minimizing the risk of pulmonary exposure. It was engineered to be compatible with a wide range of vaccine formulations, preserving their physicochemical properties, stability, and delivery efficacy. To overcome the limitations of conventional rodent models, the device was validated using (i) inx{2011}vitro human nasal cavity replicas (nasal casts) and (ii) an inx{2011}vivo rabbit model, which is more appropriate for regulatory and translational studies.</p><p><strong>Results: </strong>The spray system achieved consistent, homogeneous deposition throughout the nasal cavity without spillx{2011}over into the lower airways. Compatibility tests confirmed that the device does not alter the physicochemical characteristics or stability of a representative complex vaccine formulation. Validation in nasal casts and the rabbit model demonstrated reproducible delivery performance and supported the devicex{2019}s suitability for human use.</p><p><strong>Discussion: </strong>The presented transitory delivery platform offers a scalable, safe, and formulationx{2011}compatible solution for intranasal vaccine administration. By ensuring targeted deposition and preserving vaccine integrity, the device reinforces the potential of mucosal immunization strategies across diverse indications and facilitates the translation of nasal vaccines from prex{2011}clinical research to clinical application.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"6 ","pages":"1875011"},"PeriodicalIF":4.4,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13529731/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148876500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The biological memory buffer hypothesis: can programmable nanocarriers shape cellular memory to improve the durability of mRNA vaccines and gene therapies?","authors":"Okechukwu Paul-Chima Ugwu, Chinyere Nneoma Ugwu, Godson Emeka Anyanwu, Mariam Basajja, Maryann Chiamaka Ebuoh","doi":"10.3389/fddev.2026.1902184","DOIUrl":"10.3389/fddev.2026.1902184","url":null,"abstract":"<p><strong>Introduction: </strong>Messenger RNA vaccines and gene therapies enable rapid and programmable biological intervention, but their therapeutic durability remains variable. Existing nanomedicine research primarily evaluates delivery efficiency, targeting, RNA protection and early protein expression, which do not fully explain why some biological effects persist while others rapidly decline.</p><p><strong>Methods: </strong>This Hypothesis and Theory article presents a narrative conceptual synthesis of peer-reviewed literature on lipid nanoparticle delivery, mRNA vaccinology, RNA therapeutics, genome editing, trained innate immunity, epigenetic regulation and regenerative medicine. Evidence was integrated to develop an operational and falsifiable framework for evaluating the contribution of nanocarriers to therapeutic durability.</p><p><strong>Results: </strong>We propose the Biological Memory Buffer Hypothesis, according to which programmable nanocarriers may influence biological systems that encode, maintain or recall therapeutic information after RNA delivery. The framework distinguishes payload persistence from biological-outcome persistence and introduces three measurable constructs: therapeutic memory engineering, nanocarrier memory capacity and the therapeutic persistence window. It further proposes matched-cargo and matched-early-exposure experiments, candidate monophasic and biphasic decay models, a minimum durability reporting set and safety monitoring for maladaptive innate immune imprinting.</p><p><strong>Discussion: </strong>The framework does not assume that adaptive immune memory, trained immunity, epigenetic regulation and regenerative repair share a single molecular mechanism. Rather, it treats them as distinct biological substrates with a common functional relevance to durability. The hypothesis is falsifiable: failure to detect reproducible carrier-attributable differences under matched conditions would argue against nanocarrier memory capacity as an independent determinant. Incorporating longitudinal, tissue-specific and host-stratified durability measurements may support the rational development of longer-lasting RNA vaccines and gene therapies.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"6 ","pages":"1902184"},"PeriodicalIF":4.4,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13447438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148690326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in drug deliveryPub Date : 2026-06-04eCollection Date: 2026-01-01DOI: 10.3389/fddev.2026.1854462
Pauline Henrica Maria Janssen, Willem Antoon Rijpkema, Lorina Bisharat, Marlijn Orbons, Maarten Jaspers, Bastiaan Hendricus Jozef Dickhoff
{"title":"Microplastics matter: practical implications of the EU REACH restriction for the pharmaceutical industry.","authors":"Pauline Henrica Maria Janssen, Willem Antoon Rijpkema, Lorina Bisharat, Marlijn Orbons, Maarten Jaspers, Bastiaan Hendricus Jozef Dickhoff","doi":"10.3389/fddev.2026.1854462","DOIUrl":"10.3389/fddev.2026.1854462","url":null,"abstract":"<p><p>Synthetic polymer microparticles (SPMs), commonly referred to as microplastics, are subject to increasing restrictions due to their environmental persistence and uncertainty about potential human health effects. These substances are regulated under Regulation (EC) No 1907/2006 (REACH). Commission Regulation (EU) 2023/2055 amends REACH by introducing a restriction on SPMs in Annex XVII, including phased information and reporting obligations for in-scope uses. Although medicinal products are derogated from the market ban, these obligations have practical implications for pharmaceutical supply chains. Medicinal products containing SPMs are subject to specific reporting obligations under the REACH regulation. These obligations apply when the excipients meet the SPM definition and cannot be excluded based on criteria such as being naturally occurring, or due to their solubility or demonstrated degradability. This paper presents an operational decision-making framework that interprets the EU REACH restriction on SPM for pharmaceutical excipients and drug-delivery systems. The framework integrates regulatory definitions with testing strategies, supplier qualification processes, and downstream compliance workflows. An industry case example illustrates a combined approach using portfolio screening and biodegradation testing. This can generate evidence to support compliance decisions while preserving formulation performance.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"6 ","pages":"1854462"},"PeriodicalIF":4.4,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13275469/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148297179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in drug deliveryPub Date : 2026-06-03eCollection Date: 2026-01-01DOI: 10.3389/fddev.2026.1846904
Laura Schioppa, Cecilia Bohns Michalowski, Lucia Mamede, Romano Terrasi, Marie-France Hérent, Giulio G Muccioli, Raphaël Frédérick, Michel Frederich, Ana Beloqui, Joelle Quetin-Leclercq
{"title":"Antiparasitic triterpenic ester and ursolic acid lipid nanocapsule design, cytotoxicity, and permeability evaluation for oral delivery.","authors":"Laura Schioppa, Cecilia Bohns Michalowski, Lucia Mamede, Romano Terrasi, Marie-France Hérent, Giulio G Muccioli, Raphaël Frédérick, Michel Frederich, Ana Beloqui, Joelle Quetin-Leclercq","doi":"10.3389/fddev.2026.1846904","DOIUrl":"10.3389/fddev.2026.1846904","url":null,"abstract":"<p><strong>Introduction: </strong>Ursolic acid (UA), the antimalarial triterpenic mixture 8TTE (containing C-27 feruloyl and coumaroyl esters of ursane and oleane skeletons), and the semi-synthetic antitrypanosomal derivative ursolic acid O-phenyl propionate (UAOPP) exhibit high lipophilicity, which may limit their oral bioavailability. This study aimed to develop lipid nanocapsules (LNCs) to improve the solubility, intestinal permeability, and antiparasitic activity of these triterpenic compounds for potential oral delivery.</p><p><strong>Methods: </strong>LNCs formulations containing UA, 8TTE, and UAOPP were prepared and evaluated. A sensitive UPLCx{2013}MS method was developed and validated for selected triterpenes quantification during transport studies across Caco-2 cell monolayers [limit of detection (LOD): 2 nM; limit of quantification (LOQ): 25 nM]. Cytotoxicity and permeability studies were conducted on Caco-2 cells to assess formulation safety and intestinal transport. <i>In vitro</i> antiparasitic activity of free and formulated compounds was evaluated against <i>Plasmodium falciparum</i> and <i>Trypanosoma brucei brucei</i> (Tbb).</p><p><strong>Results and discussion: </strong>The formulations were non-toxic to Caco-2 cells at concentrations up to 2 mg/mL. Permeability studies demonstrated enhanced transport for the formulated triterpenic esters, with permeability increases of up to 2.68-fold, shifting their classification from poorly absorbed to moderately absorbed compounds in humans [apparent permeability coefficient (Papp) > 1 × 10<sup>-6</sup> cm/s]. Free UA showed the highest Papp value (4.95 × 10<sup>-6</sup> cm/s ± 1.29 × 10<sup>-7</sup>), but caused epithelial integrity disruption after 2 h of incubation and during the following 48 h, whereas formulated UA induced minimal integrity loss at the same concentration. In antiparasitic assays, blank LNCs exhibited maximum non-toxic concentrations of 165 μg/mL against <i>P. falciparum</i> and 65 μg/mL against Tbb. At these maximum concentrations, formulated UA and 8TTE showed enhanced antiplasmodial activity; however, blank LNCs produced comparable effects. In contrast, UAOPP-loaded LNCs showed significantly improved antitrypanosomal activity by approximately 20% at 2.15 μM (cell viability: 38.20% ± 5.41) compared with free UAOPP (20.38% ± 8.80). These findings suggest that LNCs represent promising oral delivery systems for lipophilic triterpenes. Further in vivo pharmacokinetic and efficacy studies are needed to confirm their therapeutic potential.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"6 ","pages":"1846904"},"PeriodicalIF":4.4,"publicationDate":"2026-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13272439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148280173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in drug deliveryPub Date : 2026-06-03eCollection Date: 2026-01-01DOI: 10.3389/fddev.2026.1778440
Wei Huang, Ziyi Wen, Konstantinos Tourmouzis, Liqun Huang, Sanford M Goldstein, Ernest Natke, Robert Honkanen, Basil Rigas
{"title":"Phosphosulindac (OXT-328) restores the suppressed corneal sensitivity in rabbits with dry eye disease: therapeutic implications.","authors":"Wei Huang, Ziyi Wen, Konstantinos Tourmouzis, Liqun Huang, Sanford M Goldstein, Ernest Natke, Robert Honkanen, Basil Rigas","doi":"10.3389/fddev.2026.1778440","DOIUrl":"10.3389/fddev.2026.1778440","url":null,"abstract":"<p><strong>Background: </strong>The symptoms of dry eye disease (DED) result from activation of ocular sensory nerves and constitute the dominant component of its clinical presentation. We assessed the effect of phosphosulindac (PS), a small molecule efficacious in the treatment of DED in preclinical models, on corneal sensitivity (CS).</p><p><strong>Methods: </strong>CS was determined with a Cochet-Bonnet esthesiometer in New Zealand white (NZW) and Dutch-belted black (DBB) rabbits. DED was induced by Concanavalin A injections into the rabbits' lacrimal glands. Changes in CS, tear osmolarity, tear break up time (TBUT) and Schirmer tear test were measured before and after DED induction. PS in various formulations (emulsions, nanoparticles and hydrogels) and other ocular drugs were applied in eye drop form to normal rabbits and those with DED.</p><p><strong>Results: </strong>nduction of DED caused a decrease in the CS, TBUT time as measured by fluorescein dye, in tear production as measured by Schirmer's tear test and an increase in tear osmolarity. PS markedly restored the suppressed CS in dry eyes. The effect was immediate, fully reversible, lasted ∼26 h and appeared dissociated from its anti-inflammatory properties. The most efficacious formulation was a Carbopol-based hydrogel; cyclodextrin-based and emulsion formulations were also effective. The most optimal dose of PS was 0.2% and the optimal pH was 6.2. None of 7 compounds structurally related to PS affected CS nor did cyclosporine, lifitegrast and artificial tears. PS does not have an anesthetic effect on the cornea. In normal eyes, PS suppressed CS and this effect was concentration-, formulation-, and pH-dependent. Two non-steroidal anti-inflammatory drugs (NSAIDs), ketorolac and bromfenac, and lidocaine suppressed CS in normal but not in dry eyes.</p><p><strong>Conclusion: </strong>PS restores the suppressed CS in dry eyes possiblely by a direct effect on corneal nerves. This effect appears unique to PS, distinct from all tested compounds including the two currently approved drugs for DED. PS, in addition to affecting CS of DED, may improve its symptoms and merits further evaluation for the treatment of DED.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"6 ","pages":"1778440"},"PeriodicalIF":4.4,"publicationDate":"2026-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13272426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148280130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in drug deliveryPub Date : 2026-06-01eCollection Date: 2026-01-01DOI: 10.3389/fddev.2026.1860678
David J Brayden, Stephen T Buckley, Andrew L Lewis
{"title":"The fourth controlled release society workshop on oral peptide administration.","authors":"David J Brayden, Stephen T Buckley, Andrew L Lewis","doi":"10.3389/fddev.2026.1860678","DOIUrl":"10.3389/fddev.2026.1860678","url":null,"abstract":"<p><p>The Controlled Release Society (CRS, www.controlledrelease.org) held its fourth iteration of research and development in oral peptide administration on 14 July 2025 in Philadelphia (United States), entitled \"Recent advances in oral peptide delivery: from molecule to market.\" The previous versions were held in 2008, 2014, and 2023 (online), so it is a topic of continuing interest to drug delivery scientists as several oral peptide products have been released in the market over the period despite the enormous technical and commercial challenges involved. The workshop was co-sponsored by Frontiers in Drug Delivery, Novo Nordisk, Johnson and Johnson, Merck, Protagonist Therapeutics, Quotient Sciences, Genentech (Roche), and Bristol-Myers Squibb. It consisted of nine talks and two roundtable sessions. The overall aim of the workshop was to provide an update on the current clinical oral peptide programmes, address mechanistic progress on permeation enhancers, and evaluate the limitations of preclinical bioassays and animal models.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"6 ","pages":"1860678"},"PeriodicalIF":4.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13266291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in drug deliveryPub Date : 2026-05-22eCollection Date: 2026-01-01DOI: 10.3389/fddev.2026.1770094
Camille Dumont, Vanessa Gonzalez, Paula Klatt, Sandrine Picco, Delphine Nombret, Marine Agisson, Euengla Uku, Thibault Saurel, Vincent Jannin
{"title":"A two-tier protection strategy for oral delivery of GLP-1 peptides: lipid-based formulation combined with enteric capsules.","authors":"Camille Dumont, Vanessa Gonzalez, Paula Klatt, Sandrine Picco, Delphine Nombret, Marine Agisson, Euengla Uku, Thibault Saurel, Vincent Jannin","doi":"10.3389/fddev.2026.1770094","DOIUrl":"10.3389/fddev.2026.1770094","url":null,"abstract":"<p><strong>Introduction: </strong>Oral delivery of peptides is a promising alternative to invasive injectable therapies, offering improved patient adherence and convenience. Glucagon-like peptide-1 (GLP-1) analogs, in particular, are highly effective for the management of type 2 diabetes mellitus and obesity, yet their oral bioavailability remains limited by enzymatic degradation and poor intestinal permeability.</p><p><strong>Methods: </strong>In this study, we aimed to design a lipid-based formulation (LBF) of the model GLP-1 analog exenatide (EXE) in its hydrophobic ion-paired (HIP) form, incorporating permeation-enhancing excipients, and evaluate its performance in enteric capsule systems.</p><p><strong>Results and discussion: </strong>EXE-HIP was prepared with sodium docusate (1:4 molar ratio), which increased lipophilicity (log P = 0.9 ± 0.2 vs. -2.9 ± 0.3 for EXE) and markedly improved solubility in lipid excipients, especially in Labrafac™ MC60, a known promoter of intestinal permeability. An optimized LBF composed of 85% Labrafac™ MC60, 10% Kolliphor® RH40, and 5% propylene glycol was developed, with a final particle size of 106 nm, and it was loaded with 6 mg/g solubilized EXE (HIP form) and 20 mg/g of sodium caprate (complementary permeation enhancer). The formulation exhibited significant protection against α-chymotrypsin-mediated degradation, which is consistent with sequestration of EXE-HIP within lipid droplets that limit enzymatic access. Short-term stability studies highlighted formulation-dependent degradation behavior, with higher impurity formation observed for solubilized EXE-HIP than for suspended EXE acetate, particularly at room temperature. To further support oral delivery, customized gelatin/HPMC-AS enteric capsules were engineered to provide a complementary two-tier protection strategy: (i) protecting the peptide and lipid phase from gastric enzymatic degradation and preventing premature dilution in gastric fluids that could displace the peptide from its protective lipid environment, while (ii) ensuring coordinated release of both EXE-HIP and the permeation enhancers at the intestinal absorption site. These capsules met the USP delayed release requirements. Overall, this work presents a promising proof-of-concept oral delivery platform that combines HIP chemistry, lipid-based formulation, and ready-to-use enteric capsule technology to enhance <i>in vitro</i> enzymatic protection of peptide therapeutics, thereby laying the groundwork for future studies to assess bioavailability and therapeutic efficacy <i>in vivo</i>.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"6 ","pages":"1770094"},"PeriodicalIF":4.4,"publicationDate":"2026-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13236653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148201136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in drug deliveryPub Date : 2026-05-12eCollection Date: 2026-01-01DOI: 10.3389/fddev.2026.1735474
Herbert H Engelhard, Olivier Balédent, Matthew T Borzage, Lydia Andrews-Jones, Thomas M Feldsien, Didier R Lefebvre
{"title":"Variability in the circulation of cerebrospinal fluid: causes and clinical implications for intraventricular drug delivery.","authors":"Herbert H Engelhard, Olivier Balédent, Matthew T Borzage, Lydia Andrews-Jones, Thomas M Feldsien, Didier R Lefebvre","doi":"10.3389/fddev.2026.1735474","DOIUrl":"10.3389/fddev.2026.1735474","url":null,"abstract":"<p><p>Understanding the many factors affecting the circulation of cerebrospinal fluid (CSF) is important for the treatment of neurological diseases, especially when considering macromolecular pharmaceuticals designed to be delivered directly into the ventricles of the brain. CSF production, pressure, flow, and absorption are tightly linked to the maintenance of brain homeostasis and function. Vascular pulsations help propel CSF through the ventricular system and subarachnoid space, with additional contributions made locally from the coordinated beating of ependymal cilia. Along with the anatomic configuration of the CSF pathways, these are critical determinants for moving therapeutic molecules and vectors to specific regions of the central nervous system (CNS) and their eventual clearance. The advent of phase contrast MRI has revolutionized the understanding of fluid flow in the human CNS, which is affected by circadian rhythm, age, molecular factors, and diseases, to name but a few. In this review, the basic principles and recent advances critical for understanding the considerable variability of CSF circulation are examined, considering differences that are encountered between healthy individuals and due to disease states. While the emphasis is on human data, illustrative comparisons with laboratory animals are made to enable translation of preclinical data to clinical use. This literature review is intended to be applicable to a wide variety of therapeutic agents, from drugs and macromolecules to adeno-associated virus (AAV) capsids, that are intended for intraventricular delivery.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"6 ","pages":"1735474"},"PeriodicalIF":4.4,"publicationDate":"2026-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13201979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148044854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}